Get the Stockscreener App
1.73
0.58%
0.01
Pre-market:
1.71
-0.02
-1.16%
Filana Therapeutics Inc stock is traded at $1.73, with a volume of 301.20K.
It is up +0.58% in the last 24 hours and up +0.00% over the past month.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
See More
Previous Close:
$1.72
Open:
$1.655
24h Volume:
301.20K
Relative Volume:
2.94
Market Cap:
$83.57M
Revenue:
-
Net Income/Loss:
$-90.97M
P/E Ratio:
-0.9184
EPS:
-1.8837
Net Cash Flow:
$-32.83M
1W Performance:
-2.26%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.655
$1.78
1-Week Range:
$1.62
$1.78
52-Week Range:
$1.62
$2.0901
Filana Therapeutics Inc Stock (FLNA) Company Profile
Name
Filana Therapeutics Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN
Compare FLNA vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FLNA
Filana Therapeutics Inc
|
1.73 | 83.57M | 0 | -90.97M | -32.83M | -1.8837 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Filana Therapeutics Inc Stock (FLNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Filana Therapeutics Inc Stock (FLNA) Latest News
Issuance/retirement of stock (net) of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
FLNA Stock Price, News & Analysis - Stock Titan
Filana Therapeutics, Inc. (FLNA) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Capital expenditures of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Free cash flow per share of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
FLNA Should I Buy - Intellectia AI
Price to book ratio of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Filana Therapeutics, Inc. Balance Sheet – NASDAQ:FLNA - TradingView
Long term debt to total equity ratio of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
EBIT of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Number of shareholders of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Filana Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | FLNA * | US14817C1071 - marketscreener.com
Filana Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | PX91 | US14817C1071 - marketscreener.com
Changes in working capital of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Filana Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | FLNA | US14817C1071 - marketscreener.com
Non-controlling/minority interest of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Taxes of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
FLNA Technical Analysis & Stock Price Forecast - Intellectia AI
Filana Therapeutics (FLNA) Stock Analysis Report | Financials & Insights - Benzinga
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - marketscreener.com
Cassava Sciences, Inc. Class Action: The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - marketscreener.com
Filana Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | PX91 | US14817C1071 - marketscreener.com
Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your RightsSAVA - marketscreener.com
Filana Therapeutics Inc (FLNA-Q) Profile - The Globe and Mail
Filana Therapeutics Inc FLNA-Q Earnings - The Globe and Mail
Filana Therapeutics Inc (FLNA-Q) Insider Trade Summaries - The Globe and Mail
Filana Therapeutics Inc (FLNA-Q) Statistics - The Globe and Mail
Net income before discontinued operations of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Total liabilities & shareholders' equities of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - marketscreener.com
Filana Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | SAVA * | US14817C1071 - marketscreener.com
Filana Therapeutics, Inc. Statistics – NASDAQ:FLNA - TradingView
Filana Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | SAVA * | US14817C1071 - marketscreener.com
Total liabilities of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Total liabilities & shareholders' equities of Filana Therapeutics, Inc. – BOATS:FLNA - TradingView
Return on assets % of Filana Therapeutics, Inc. – BOATS:FLNA - TradingView
After tax other income/expense of Filana Therapeutics, Inc. – BOATS:FLNA - TradingView
FLNA Forecast — Price Target — Prediction for 2027 - TradingView
Non-controlling/minority interest of Filana Therapeutics, Inc. – BOATS:FLNA - TradingView
Filana Therapeutics, Inc. Income Statement – BOATS:FLNA - TradingView
EBIT per share of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Filana Therapeutics, Inc.: Top Mutual Funds Holders | FLNA | US14817C1071 - marketscreener.com
Filana Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | FLNA | US14817C1071 - marketscreener.com
symbol__ Stock Quote Price and Forecast - cnn.com
FLNA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Net debt of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
FLNA PE Ratio & Valuation, Is FLNA Overvalued - Intellectia AI
Filana Therapeutics (NASDAQ: SAVA) pivots to TSC epilepsy amid FDA clinical hold - Stock Titan
Free cash flow of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Cash from investing activities of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
CapEx per share of Filana Therapeutics, Inc. – NASDAQ:FLNA - TradingView
Filana Therapeutics Inc Stock (FLNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):